BCAB
insider transactionsBioAtla, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
Jay M Short PHD KEY
Chief Executive Officer
$1.0K
259 sh · $3.93
Own -0%
-
Other·F
Chief Financial Officer
$322
82 sh · $3.93
Own -1%
-
Other·F
Chief Medical Officer
$527
134 sh · $3.93
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 31, 2026 | Jay M Short PHD KEY | Other F | 259 | $1.0K |
| May 31, 2026 | Christian Vasquez KEY | Other F | 82 | $322 |
| May 31, 2026 | Eric Sievers | Other F | 134 | $527 |
About BCAB insider trading
This page tracks insider transactions for BioAtla, Inc. (BCAB) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.